OasisLMS

This product is: 

• Free for conference attendees.
• Available for purchase for those that did NOT attend the conference. 

For assistance, email: education@iaslc.org

The IASLC 2026 Hot Topic Meeting: Resistance to Immunotherapy is a biannual international meeting dedicated to the latest preclinical and translational advances in the earliest phases of lung carcinogenesis. This meeting brings together leading scientists, clinicians, and multidisciplinary experts to explore the biological foundations of precancerous lesions and early-stage lung tumors.

Over the course of this meeting, we will examine the biological mechanisms underlying primary and acquired resistance to immunotherapy, explore tumor–immune interactions and the role of the tumor microenvironment, and discuss emerging biomarkers and novel therapeutic strategies to overcome resistance. Through expert-led presentations, panel discussions, and interactive sessions, our goal is to bridge cutting-edge discovery with clinical application—accelerating progress toward more durable and effective immunotherapy outcomes for patients.

The meeting is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer and other thoracic malignancies, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, physician assistants and nurses.

Upon completion of this activity, the participants should be able to: 

• Review the latest advancements in understanding biological mechanisms that drive primary and acquired resistance to immunotherapy
• Examine tumor-immune interactions and the role of the tumor microenvironment
• Evaluation the basic research on oncogenesis and biology of disease, preclinical therapeutic research, and highlights of ongoing clinical translation. 
• Provide researchers and medical oncologists with the knowledge needed to innovate and improve patient outcomes.

• Fabrizio Bianchi, PhD, IRCCS Casa Sollievo della Sofferenza Hospital | Italy
• Ferdinando Cerciello, MD, PhD, Bern University Hospital | Germany
• Floris Dammeijer, MD, PhD, Erasmus Medical Center | Netherlands
• Patrick Forde, MD, PhD, Trinity College | Ireland
• Sandra Ortiz-Cuaran, PhD, Cancer Center of Lyon | France

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

For assistance with this activity, please email: education@iaslc.org.